The role of Janus kinase signaling in the pathology of atopic dermatitis

J Allergy Clin Immunol. 2023 Dec;152(6):1394-1404. doi: 10.1016/j.jaci.2023.07.010. Epub 2023 Aug 1.

Abstract

Atopic dermatitis (AD) is a heterogeneous, chronic, relapsing, inflammatory skin disease associated with considerable physical, psychological, and economic burden. The pathology of AD includes complex interactions involving abnormalities in immune and skin barrier genes, skin barrier disruption, immune dysregulation, microbiome disturbance, and other environmental factors. Many of the cytokines involved in AD pathology, including IL-4, IL-13, IL-22, IL-31, thymic stromal lymphopoietin, and IFN-γ, signal through the Janus kinase (JAK)-signal transducer and activation of transcription (STAT) pathway. The JAK family includes JAK1, JAK2, JAK3, and tyrosine kinase 2; the STAT family includes STAT1, STAT2, STAT3, STAT4, STAT5A/B, and STAT6. Activation of the JAK-STAT pathway has been implicated in the pathology of several immune-mediated inflammatory diseases, including AD. However, the exact mechanisms of JAK-STAT involvement in AD have not been fully characterized. This review aims to discuss current knowledge about the role of the JAK-STAT signaling pathway and, specifically, the role of JAK1 in the pathology and symptomology of AD.

Keywords: Atopic dermatitis; JAK-STAT; pathology; symptomology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / metabolism
  • Dermatitis, Atopic*
  • Humans
  • Janus Kinase 1 / metabolism
  • Janus Kinases* / metabolism
  • STAT Transcription Factors / metabolism
  • Signal Transduction

Substances

  • Janus Kinases
  • STAT Transcription Factors
  • Janus Kinase 1
  • Cytokines